{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:38:36Z","timestamp":1793191116108,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rmed.2025.108203","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:52:09Z","timestamp":1749657129000},"page":"108203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-6703","authenticated-orcid":false,"given":"Susanne","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Erik Julius","family":"H\u00e5kansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Baastrup","family":"Soendergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sofie","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Martin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Lock","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Makowska","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Rikard","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3268-785X","authenticated-orcid":false,"given":"Anna","family":"von B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-347X","authenticated-orcid":false,"given":"Barbara","family":"Bonnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lycely","family":"Dongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Vijdea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8689-3695","authenticated-orcid":false,"given":"Charlotte Suppli","family":"Ulrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2025.108203_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.108203_bib2","first-page":"687","article-title":"Prevalence and management of severe asthma in the Nordic countries \u2013 findings from the NORDSTAR cohort","author":"Hansen","year":"2023","journal-title":"ERJ Open Res"},{"issue":"10379","key":"10.1016\/j.rmed.2025.108203_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2025.108203_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaip.2014.05.005","article-title":"The prevalence of severe asthma and low asthma control among Danish adults","volume":"2","author":"von B\u00fclow","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.108203_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001437","article-title":"Beyond direct costs: individual and societal financial burden of asthma in young adults in a Danish nationwide study","volume":"10","author":"H\u00e5kansson","year":"2023","journal-title":"BMJ Open Resp Res"},{"issue":"2","key":"10.1016\/j.rmed.2025.108203_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.rmed.2025.108203_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10209","key":"10.1016\/j.rmed.2025.108203_bib8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.rmed.2025.108203_bib9","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.rmed.2025.108203_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108203_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108203_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221133689","article-title":"Comparison between clinical trials and real-world evidence studies on biologics for severe asthma","volume":"50","author":"Menzella","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.rmed.2025.108203_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.108203_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real\u2010life French multi\u2010centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2025.108203_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program","volume":"14","author":"Campisi","year":"2021","journal-title":"JAA"},{"issue":"7","key":"10.1016\/j.rmed.2025.108203_bib16","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.108203_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.rmed.2025.108203_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108203_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2025.108203_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1183\/23120541.00238-2022","article-title":"Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register","volume":"8","author":"Soendergaard","year":"2022","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.rmed.2025.108203_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti\u2013IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2025.108203_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108203_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2020.1842117","article-title":"The Danish severe asthma register: an electronic platform for severe asthma management and research","volume":"8","author":"Hansen","year":"2021","journal-title":"European Clinical Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2025.108203_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.108203_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108203_bib27","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","volume":"S2213219824010638","author":"Pavord","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.108203_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108203_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"10423","key":"10.1016\/j.rmed.2025.108203_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2025.108203_bib31","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2024.03.031","article-title":"Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma","volume":"12","author":"Pavord","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.rmed.2025.108203_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.108203_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106938","article-title":"Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline","volume":"202","author":"Bourdin","year":"2022","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108203_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1513\/pats.200903-013ST","article-title":"An official American thoracic society workshop report: obesity and asthma","volume":"7","author":"Dixon","year":"2010","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"7","key":"10.1016\/j.rmed.2025.108203_bib35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","article-title":"Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts","volume":"4","author":"Peters","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108203_bib36","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/all.16002","article-title":"Lung function trajectories in a cohort of patients with moderate\u2010to\u2010severe asthma on mepolizumab, omalizumab, or dupilumab","volume":"79","author":"Nopsopon","year":"2024","journal-title":"Allergy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125002653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:32:39Z","timestamp":1764919959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125002653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0954611125002653"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108203","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108203"}}